Avidity Biosciences
10578 Science Center Drive
Suite 125
San Diego
California
92121
United States
Tel: 858-401-7900
Website: http://www.aviditybiosciences.com/
Email: info@aviditybio.com
About Avidity Biosciences
Our vision is to profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics. We’re utilizing our proprietary AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies (mAbs) with the precision of oligonucleotide-based therapies in order to redefine RNA therapeutics and more effectively target underlying genetic drivers of diseases. We are delivering on this vision by investing in our platform, our pipeline and our people.
Our commitment to rigorous and innovative science is matched only by our passion to see patients’ lives changed. We consistently challenge ourselves to Be AVID – Agile, Visionary, Integrated and Diverse.
We are assembling a diverse team experienced in rare disease and RNA therapies. Our team members bring expertise in research, development and commercial execution. We are focused on cultivating the right team to not only grow the company, but also to reflect the communities we serve. We are dedicated to employing and retaining a diverse and inclusive workforce at all levels of the organization to not only ensure that different backgrounds and perspectives are being heard and acted upon, but that our employees also feel understood, accepted and valued.
BeAVID
89 articles with Avidity Biosciences
-
Avidity Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
12/22/2020
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs ™ ), today announced that Sarah Boyce , President and Chief Executive Officer, is scheduled to present at the 39 th Annual J.P. Morgan Healthcare Confer
-
Avidity Biosciences Announced Addition to the Nasdaq Biotechnology Index
12/21/2020
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI), which became effective prior to market open on Monday, Decembe
-
Avidity Biosciences Reports Third Quarter 2020 Financial Results and Recent Highlights
11/10/2020
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the quarter ended September 30, 2020 and highlighted recent corporate progress.
-
Avidity Biosciences to Present at the Credit Suisse 29th Annual Virtual Healthcare Conference 2020
11/5/2020
Avidity Biosciences, Inc. announced that Sarah Boyce, President and Chief Executive Officer, will be presenting at the Credit Suisse 29th Annual Virtual Healthcare Conference 2020 on Thursday, November 12th, 2020 at 8:45am PST.
-
Avidity Biosciences to Present at the Virtual Chardan 4th Annual Genetic Medicines Conference 2020
9/28/2020
- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs ™ ), today announced that Sarah Boyce , President and Chief Executive Officer, Arthur Levin , Ph.D., Chief Scientific Officer, and Mike MacLean , Chi
-
Avidity Biosciences to Present at Several Upcoming Virtual Scientific Meetings
9/14/2020
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will present at several upcoming virtual scientific meetings.
-
Avidity Biosciences Enters into Collaboration to Study the Natural History of Myotonic Dystrophy Type 1
9/8/2020
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced it entered into a collaboration supporting END-DM1, a natural history study to advance the understanding of disease progression in patients w
-
Avidity Biosciences to Present at the 2020 Wells Fargo Virtual Healthcare Conference
9/3/2020
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs ™ ), today announced that Sarah Boyce , Avidity's President and CEO, will participate in a fireside chat at the 2020 Wells Fargo Virtual Healthcare Conference
-
Avidity Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights
8/10/2020
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the quarter and six months ended June 30, 2020 and highlighted recent corporate progress.
-
Avidity Biosciences Appoints Jae Kim, M.D. as Chief Medical Officer
7/27/2020
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), announced today the appointment of Jae Kim , M.D. as Chief Medical Officer. In his new role, Dr. Kim will be responsible for leading and expanding Avidity's AOC
-
Avidity Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
6/16/2020
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced the closing of its initial public offering of 16,560,000 shares of common stock,
-
BioSpace takes a look at some of the most recent IPO plans from companies across the globe.
-
Avidity Biosciences Announces Pricing of Initial Public Offering
6/11/2020
Avidity Biosciences, Inc. (Nasdaq:RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced the pricing of its initial public offering of 14,400,000 shares of common stock at a public offering price of $18.00 per share.
-
Avidity Biosciences Appoints Michael MacLean as Chief Financial Officer
5/19/2020
Avidity Biosciences (Avidity), a privately-held biopharmaceutical company pioneering Antibody Oligonucleotide Conjugates (AOCs™), announced today the appointment of Michael MacLean as Chief Financial Officer.
-
Avidity Biosciences Appoints Carsten Boess to its Board of Directors
4/13/2020
Avidity Biosciences (Avidity), a privately-held biopharmaceutical company pioneering Antibody Oligonucleotide Conjugates (AOCs™), announced today the appointment of Carsten Boess to its board of directors. Mr. Boess, who has nearly thirty years of industry experience as a finance executive and board member, brings a wealth of experien
-
Avidity Biosciences Announces Presentations at Upcoming Investor Conferences
2/24/2020
SAN DIEGO , Feb. 24, 2020 /PRNewswire/ -- Avidity Biosciences (Avidity), a privately-held biotechnology company pioneering Antibody Oligonucleotide Conjugates (AOCs™), announced today that Sarah Boyce , Avidity's President and CEO, will present a company overview at two upcoming investor conferences: 9 th Annual SVB Leerink Global
-
Avidity Biosciences Appoints Joseph Baroldi as Chief Operating Officer
2/12/2020
SAN DIEGO , Feb. 12, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Avidity), a privately-held biotechnology company pioneering Antibody Oligonucleotide Conjugates (AOCs™), announced today the appointment of Joseph Baroldi as Chief Operating Officer. "We are thrilled to welcome Joe to the Avidity team," said Sarah Boyce , Preside
-
It can be a bit difficult to predict exactly what the big stories out of the JP Morgan Healthcare Conference are going to be. There’s no telling if some surprise deal will take the air out of the room, but here’s a look at some of the top presentations.
-
Avidity Biosciences Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference
1/7/2020
Avidity Biosciences announced that it will present at the 38th Annual J.P. Morgan Healthcare Conference being held January 13-16, 2020 in San Francisco, CA.
-
Avidity Biosciences Completes $100 Million Series C Financing
11/13/2019
Avidity Biosciences, a biotechnology company pioneering Antibody-Oligonucleotide Conjugates (AOCs™) for the treatment of rare muscle disorders and other serious diseases, announced the completion of a $100 million Series C financing.